We are a Vancouver, Canada-based biotech firm focused on developing our innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe our proprietary platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe in vivo delivery of active gene editing machinery into target tissues. We have secured the exclusive worldwide license from the University of British Columbia to our foundational technology, and continue to build out our intellectual property and patent portfolio through additional research and development. Currently, we are focused on continued development of our innovative delivery platform for therapeutic gene editing cargoes. We have undertaken key research activities to support the development of our platform, achieving significant proof of concept data for effective in vivo gene editing. We have approached our studies in a systematic way that enables us to iterate on our foundational system. We are actively using our platform to develop strategies for multiple disease indications, as well as creating new product modifications. We are excited to be part of the Vancouver biotechnology community, in a city that is rapidly emerging as one of the most vibrant innovation hubs in North America.